182 related articles for article (PubMed ID: 35012557)
1. Diverse psychotropic substances detected in drug and drug administration equipment samples submitted to drug checking services in Toronto, Ontario, Canada, October 2019-April 2020.
Scarfone KM; Maghsoudi N; McDonald K; Stefan C; Beriault DR; Wong E; Evert M; Hopkins S; Leslie P; Watson TM; Werb D;
Harm Reduct J; 2022 Jan; 19(1):3. PubMed ID: 35012557
[TBL] [Abstract][Full Text] [Related]
2. Emerging synthetic cannabinoids detected by a drug checking service in Toronto, Canada.
Scarfone KM; Maghsoudi N; McDonald K; Thompson H; Stefan C; Beriault DR; Werb D; Bowles JM
Clin Toxicol (Phila); 2022 Aug; 60(8):979-984. PubMed ID: 35546568
[TBL] [Abstract][Full Text] [Related]
3. Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications.
Bowles JM; McDonald K; Maghsoudi N; Thompson H; Stefan C; Beriault DR; Delaney S; Wong E; Werb D
Harm Reduct J; 2021 Oct; 18(1):104. PubMed ID: 34645480
[TBL] [Abstract][Full Text] [Related]
4. Evaluating networked drug checking services in Toronto, Ontario: study protocol and rationale.
Maghsoudi N; McDonald K; Stefan C; Beriault DR; Mason K; Barnaby L; Altenberg J; MacDonald RD; Caldwell J; Nisenbaum R; Leece P; Watson TM; Tupper KW; Kufner L; Scheim AI; Werb D;
Harm Reduct J; 2020 Jan; 17(1):9. PubMed ID: 32204713
[TBL] [Abstract][Full Text] [Related]
5. Drug checking services as a surveillance tool for clinical laboratories: Examining trends in the unregulated fentanyl supply.
Delaney SR; Konforte D; Stefan C; Palaty J; Sun D; McDonald K; Thompson H; Werb D; Beriault DR
Clin Biochem; 2023 Jan; 111():11-16. PubMed ID: 36379241
[TBL] [Abstract][Full Text] [Related]
6. A new quantitative drug checking technology for harm reduction: Pilot study in Vancouver, Canada using paper spray mass spectrometry.
Borden SA; Saatchi A; Vandergrift GW; Palaty J; Lysyshyn M; Gill CG
Drug Alcohol Rev; 2022 Feb; 41(2):410-418. PubMed ID: 34347332
[TBL] [Abstract][Full Text] [Related]
7. An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program using point-of-care and confirmatory methods.
Laing MK; Ti L; Marmel A; Tobias S; Shapiro AM; Laing R; Lysyshyn M; Socías ME
Int J Drug Policy; 2021 Jul; 93():103169. PubMed ID: 33627302
[TBL] [Abstract][Full Text] [Related]
8. Drug checking as a potential strategic overdose response in the fentanyl era.
Laing MK; Tupper KW; Fairbairn N
Int J Drug Policy; 2018 Dec; 62():59-66. PubMed ID: 30359874
[TBL] [Abstract][Full Text] [Related]
9. Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian settings.
Ti L; Tobias S; Maghsoudi N; Milloy MJ; McDonald K; Shapiro A; Beriault D; Stefan C; Lysyshyn M; Werb D
Drug Alcohol Rev; 2021 May; 40(4):580-585. PubMed ID: 33354869
[TBL] [Abstract][Full Text] [Related]
10. Drug checking use and interest among people who inject drugs in Toronto, Canada.
Rammohan I; Bouck Z; Fusigboye S; Bowles J; McDonald K; Maghsoudi N; Scheim A; Werb D
Int J Drug Policy; 2022 Sep; 107():103781. PubMed ID: 35803177
[TBL] [Abstract][Full Text] [Related]
11. Current attitudes toward drug checking services and a comparison of expected with actual drugs present in street drug samples collected from opioid users.
Swartz JA; Lieberman M; Jimenez AD; Mackesy-Amiti ME; Whitehead HD; Hayes KL; Taylor L; Prete E
Harm Reduct J; 2023 Jul; 20(1):87. PubMed ID: 37420196
[TBL] [Abstract][Full Text] [Related]
12. Variability in the unregulated opioid market in the context of extreme rates of overdose.
Larnder A; Saatchi A; Borden SA; Moa B; Gill CG; Wallace B; Hore D
Drug Alcohol Depend; 2022 Jun; 235():109427. PubMed ID: 35405459
[TBL] [Abstract][Full Text] [Related]
13. The potential impacts of community drug checking within the overdose crisis: qualitative study exploring the perspective of prospective service users.
Wallace B; van Roode T; Pagan F; Hore D; Pauly B
BMC Public Health; 2021 Jun; 21(1):1156. PubMed ID: 34134698
[TBL] [Abstract][Full Text] [Related]
14. Effect of witnessing an overdose on the use of drug checking services among people who use illicit drugs in Vancouver, Canada.
Beaulieu T; Hayashi K; Nosova E; Milloy MJ; DeBeck K; Wood E; Kerr T; Ti L
Am J Drug Alcohol Abuse; 2020 Jul; 46(4):506-511. PubMed ID: 31983241
[TBL] [Abstract][Full Text] [Related]
15. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting.
Tupper KW; McCrae K; Garber I; Lysyshyn M; Wood E
Drug Alcohol Depend; 2018 Sep; 190():242-245. PubMed ID: 30064061
[TBL] [Abstract][Full Text] [Related]
16. A survey of North American drug checking services operating in 2022.
Park JN; Tardif J; Thompson E; Rosen JG; Lira JAS; Green TC
Int J Drug Policy; 2023 Nov; 121():104206. PubMed ID: 37797571
[TBL] [Abstract][Full Text] [Related]
17. Paper spray mass spectrometry: A new drug checking tool for harm reduction in the opioid overdose crisis.
Vandergrift GW; Gill CG
J Mass Spectrom; 2019 Sep; 54(9):729-737. PubMed ID: 31432563
[TBL] [Abstract][Full Text] [Related]
18. Fentanyl Concentration in Drug Checking Samples and Risk of Overdose Death in Vancouver, Canada.
Kennedy MC; Dong H; Tobias S; Buxton JA; Lysyshyn M; Tupper KW; Ti L
Am J Prev Med; 2024 Jan; 66(1):10-17. PubMed ID: 37633426
[TBL] [Abstract][Full Text] [Related]
19. Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada.
Klaire S; Janssen RM; Olson K; Bridgeman J; Korol EE; Chu T; Ghafari C; Sabeti S; Buxton JA; Lysyshyn M
Int J Drug Policy; 2022 Aug; 106():103741. PubMed ID: 35671687
[TBL] [Abstract][Full Text] [Related]
20. Responding to changes in the unregulated drug supply: the need for a dynamic approach to drug checking technologies.
Bhuiyan I; Tobias S; Ti L
Am J Drug Alcohol Abuse; 2023 Nov; 49(6):685-690. PubMed ID: 37506334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
